New Delhi, India, November 7 (ANI): Revised maximum retail prices for key anti-cancer formulations will take effect across the country on November 9, delivering estimated annual financial relief of more than Rs. 3,500 crore to patients and their families.
The price reductions follow a regulatory decision by the National Pharmaceutical Pricing Authority (NPPA), which functions under the Department of Pharmaceuticals in the Ministry of Chemicals and Fertilizers, to cap trade margins on the retail prices of 137 anti-cancer medicines.
The action is based on recommendations submitted by an expert committee constituted by the Directorate General of Health Services (DGHS) under the Ministry of Health and Family Welfare.
According to the Ministry of Chemicals and Fertilizers, the price adjustments will translate into immediate household savings on critical cancer treatments.
“As a result of the price reductions to be effected from November 9, 2026, the estimated annual savings to consumers would be Rs. 3,502.31 crore,” the ministry stated.
To date, 76 pharmaceutical manufacturers have submitted revised pricing structures covering 1,225 anti-cancer formulations across 121 individual drugs. Price decreases apply directly to 1,031 formulations, with 600 distinct brands recording reductions exceeding 50%, and the sharpest recorded decrease reaching 96.45%.
The ministry described the policy intervention as a key component of its efforts to improve access to health care.
“Trade Margin Rationalization (TMR) of non-scheduled anti-cancer medicines is an important step taken by the government in its continued efforts to improve affordability and accessibility of essential anti-cancer medicines for cancer care,” the ministry noted.
The price-capping framework also covers treatments that are not yet commercially available in the domestic health care market. Between 10 and 15 of the 137 identified drugs are awaiting rollout in India, but the ministry affirmed that Trade Margin Rationalization will apply to those products as well, immediately upon their market release.
The regulatory provisions, enacted through notification SO 5690 (E) dated October 17, 2026, will remain effective until further orders. Under these norms, drug manufacturers retain the option to claim annual price adjustments under Paragraph 20(1) of the Drugs (Prices Control) Order, 2013, provided the products strictly adhere to the 30% trade margin threshold.
Compliance measures require every retailer, pharmacy dealer, hospital and medical institution to prominently display the revised price lists on their websites and at their physical facilities.
State drug controllers will oversee compliance by manufacturers, retail dealers and hospitals. Consumers can track verified pricing information through the Pharma Sahi Daam mobile application and the official NPPA portal, where they can also submit reports of noncompliance. (ANI)
About The Author
